These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38852646)

  • 1. INPP4B suppresses HER2-induced mesenchymal transition in HER2+ breast cancer and enhances sensitivity to Lapatinib.
    Qu N; Wang G; Su Y; Chen B; Zhou D; Wu Y; Yuan L; Yin M; Liu M; Peng Y; Zhou W
    Biochem Pharmacol; 2024 Aug; 226():116347. PubMed ID: 38852646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TCF12-regulated GRB7 facilitates the HER2+ breast cancer progression by activating Notch1 signaling pathway.
    Wang G; Wu Y; Su Y; Qu N; Chen B; Zhou D; Yuan L; Yin M; Liu M; Zhou W
    J Transl Med; 2024 Aug; 22(1):745. PubMed ID: 39113057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.
    Gril B; Palmieri D; Bronder JL; Herring JM; Vega-Valle E; Feigenbaum L; Liewehr DJ; Steinberg SM; Merino MJ; Rubin SD; Steeg PS
    J Natl Cancer Inst; 2008 Aug; 100(15):1092-103. PubMed ID: 18664652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. INPP4B promotes PI3Kα-dependent late endosome formation and Wnt/β-catenin signaling in breast cancer.
    Rodgers SJ; Ooms LM; Oorschot VMJ; Schittenhelm RB; Nguyen EV; Hamila SA; Rynkiewicz N; Gurung R; Eramo MJ; Sriratana A; Fedele CG; Caramia F; Loi S; Kerr G; Abud HE; Ramm G; Papa A; Ellisdon AM; Daly RJ; McLean CA; Mitchell CA
    Nat Commun; 2021 May; 12(1):3140. PubMed ID: 34035258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Gi/o protein-coupled receptor signaling blocks HER2-induced breast cancer development and enhances HER2-targeted therapy.
    Lyu C; Ye Y; Lensing MM; Wagner KU; Weigel RJ; Chen S
    JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34343132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
    Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
    Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers.
    Fedele CG; Ooms LM; Ho M; Vieusseux J; O'Toole SA; Millar EK; Lopez-Knowles E; Sriratana A; Gurung R; Baglietto L; Giles GG; Bailey CG; Rasko JE; Shields BJ; Price JT; Majerus PW; Sutherland RL; Tiganis T; McLean CA; Mitchell CA
    Proc Natl Acad Sci U S A; 2010 Dec; 107(51):22231-6. PubMed ID: 21127264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
    Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
    Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
    Formisano L; Nappi L; Rosa R; Marciano R; D'Amato C; D'Amato V; Damiano V; Raimondo L; Iommelli F; Scorziello A; Troncone G; Veneziani B; Parsons SJ; De Placido S; Bianco R
    Breast Cancer Res; 2014 May; 16(3):R45. PubMed ID: 24887236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lapatinib inhibits doxorubicin induced migration of HER2-positive breast cancer cells.
    Chintalaramulu N; Vadivelu R; Nguyen NT; Cock IE
    Inflammopharmacology; 2020 Oct; 28(5):1375-1386. PubMed ID: 32378049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT.
    Li H; Wang J; Yi Z; Li C; Wang H; Zhang J; Wang T; Nan P; Lin F; Xu D; Qian H; Ma F
    Eur J Cancer; 2021 Mar; 145():92-108. PubMed ID: 33429148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acetyltanshinone IIA is more potent than lapatinib in inhibiting cell growth and degrading HER2 protein in drug-resistant HER2-positive breast cancer cells.
    Huang B; Yip WK; Wei N; Luo KQ
    Cancer Lett; 2020 Oct; 490():1-11. PubMed ID: 32585412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition.
    Brown WS; Akhand SS; Wendt MK
    Oncotarget; 2016 Dec; 7(50):83424-83436. PubMed ID: 27825137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib.
    Ding J; Yao Y; Huang G; Wang X; Yi J; Zhang N; Liu C; Wang K; Zhang Y; Wang M; Liu P; Ye M; Li M; Cheng H
    Cancer Lett; 2020 Apr; 475():53-64. PubMed ID: 32006616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines.
    Puig T; Aguilar H; Cufí S; Oliveras G; Turrado C; Ortega-Gutiérrez S; Benhamú B; López-Rodríguez ML; Urruticoechea A; Colomer R
    Breast Cancer Res; 2011; 13(6):R131. PubMed ID: 22177475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.
    Nencioni A; Cea M; Garuti A; Passalacqua M; Raffaghello L; Soncini D; Moran E; Zoppoli G; Pistoia V; Patrone F; Ballestrero A
    PLoS One; 2010 Feb; 5(2):e9024. PubMed ID: 20126311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (-)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo.
    Siddique AB; Ebrahim HY; Akl MR; Ayoub NM; Goda AA; Mohyeldin MM; Nagumalli SK; Hananeh WM; Liu YY; Meyer SA; El Sayed KA
    Nutrients; 2019 Feb; 11(2):. PubMed ID: 30781364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer.
    Liu J; Chen X; Ward T; Mao Y; Bockhorn J; Liu X; Wang G; Pegram M; Shen K
    Int J Biochem Cell Biol; 2016 Feb; 71():12-23. PubMed ID: 26643609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
    Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
    Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.
    Dupouy S; Doan VK; Wu Z; Mourra N; Liu J; De Wever O; Llorca FP; Cayre A; Kouchkar A; Gompel A; Forgez P
    Oncotarget; 2014 Sep; 5(18):8235-51. PubMed ID: 25249538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.